MonoSol Rx and Midatech Ltd Complete Transbuccal Insulin Delivery Study in Primate Diabetes Model
MonoSol Rx and Midatech Group Ltd. announced positive results from a pre-clinical study of insulin PharmFilm, the first-ever oral insulin film formulation to transbuccally deliver an active therapeutic dose of insulin in a diet-induced diabetic primate model.
The two companies are developing insulin PharmFilm under a partnership that leverages MonoSol Rx’s PharmFilm and Midatech’s biocompatible nanoparticles to develop orally bioavailable formulations of peptides and drugs. This partnership includes a joint venture set up to focus on the development and commercialization of products combining the two companies’ respective technologies in the diabetes field.
The transbuccal Pharmfilm delivery of insulin in this Rhesus monkey study represents the most advanced proof-of-concept to date for any investigative oral buccal insulin formulation, and confirms previously announced positive results in two porcine studies. Primates in the study were administered insulin PharmFilm transbuccally, or “inside the cheek,” with data confirming delivery of an active therapeutic dose of insulin.
Other news from the department research and development
